Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14459215 | 0.84 | KIF11 (0.47) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL14459222 | 0.83 | KIF11 (0.51) | KIF11DNMT1 | |
| SCHEMBL3056174 | 0.83 | GRM2 (0.46) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL3056170 | 0.83 | GRM2 (0.46) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL31537531 | 0.83 | GRM2 (0.46) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL14459219 | 0.83 | KIF11 (0.45) | KIF11ALPIPKMPTGS1XIAP | |
| SCHEMBL14537461 | 0.78 | KIF11 (0.46) | KIF11CYP1A2TSHRALPIPKM | |
| SCHEMBL2256055 | 0.75 | IDO1 (0.59) | KIF11CYP1A2TSHRALPIPKM | |
| SCHEMBL19367971 | 0.75 | IDO1 (0.59) | KIF11CYP1A2TSHRALPIPKM | |
| SCHEMBL2256059 | 0.75 | IDO1 (0.59) | KIF11CYP1A2TSHRALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211296-B2 | Therapeutic compounds for blocking DNA synthesis of POX viruses | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130338117-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-12-19 | — | — | US | disclosed |
| US-8524719-B2 | Therapeutic compounds for blocking DNA synthesis of pox viruses | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-09-03 | — | — | US | disclosed |
| US-8349899-B1 | Selective inhibitors of EG5 motors and methods of use | ARROWHEAD CENTER, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349899-B1 | Selective inhibitors of EG5 motors and methods of use | ARROWHEAD CENTER, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120322770-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-20 | — | — | US | disclosed |
| US-8278342-B2 | Therapeutic compounds for blocking DNA synthesis of pox viruses | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-11 | — | — | US | disclosed |
| WO-2009008906-A2 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322770-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | KIF11 4204/4885CYP1A2 2970/4885TSHR 4583/4885 |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | KIF11 4204/4885CYP1A2 2970/4885TSHR 4583/4885 |
| US-20130338117-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | KIF11 4204/4885CYP1A2 2970/4885TSHR 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.